Global Leading Market Research Publisher QYResearch announces the release of its latest report "Major Depressive Disorder - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032". Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Major Depressive Disorder market, including market size, share, demand, industry development status, and forecasts for the next few years. The global market for Major Depressive Disorder was estimated to be worth US$ million in 2025 and is projected to reach US$ million, growing at a CAGR of % from 2026 to 2032. Major depressive disorder, also known as major depression and clinical depression, is a mental disorder characterized by loss of interest and pleasure in enjoyable environment. People are affected in different ways by major depression. Some people have trouble sleeping, feel agitated and irritable, and have sudden weight loss. Moreover, they can have other mental and physical symptoms such as fatigue, memory loss, feeling of hopelessness, body aches, headaches, and thoughts of suicide. Market Opportunities and Driving Forces — Which Clinical Pain Points Are Reshaping Treatment Choices? Multi-pathway innovation has brought more diverse, accessible, and rapid interventions to clinical practice. Traditional monoaminergic antidepressants are being continuously optimized throughout their lifecycle by leading companies—such as Pfizer's desvenlafaxine and Eli Lilly's duloxetine—which have accumulated extensive real-world experience in combination and personalized use. New mechanism drugs targeting the glutamatergic system (e.g., the FDA-approved intranasal ketamine derivative) provide faster-acting solutions for acute suicidal symptoms, pushing medical institutions to strengthen evaluation and follow-up capacities. On the regulatory side, updated labeling requirements, renewed black-box warnings, and graded management guidelines are driving structured oversight of prescribing and medication safety. Meanwhile, national and regional mental health action plans, hotlines, and specialized treatment centers provide policy-level endorsement for service expansion, forming a positive cycle of "demand expansion – supply upgrading – quality control." Industry Chain / Supply Chain — From Raw Materials to Clinical Services, Who Holds the Key Positions? Upstream activities include active pharmaceutical ingredients, formulation technologies (extended-release, controlled-release, intranasal systems), and digital adherence or device-integrated monitoring tools. The midstream comprises brand owners, manufacturers, and co-commercialization partners—such as Pfizer (PRISTIQ/desvenlafaxine), Eli Lilly (CYMBALTA/duloxetine), H. Lundbeck & Takeda (vortioxetine, with Takeda leading commercialization in the U.S. and Lundbeck as MAH and manufacturer in the EU), and Otsuka & Lundbeck (brexpiprazole for adjunctive therapy in Major Depressive Disorder). Downstream, multi-tiered healthcare institutions, psychotherapy providers, pharmacies, and reimbursement systems jointly shape the adherence ecosystem. The market launch of rapid-acting antidepressants has also prompted hospitals to establish crisis intervention and monitoring protocols. In essence, value-chain collaboration under regulatory supervision integrates "onset speed – tolerability – safety monitoring – long-term maintenance" into executable clinical service products. Market Segmentation Trends — Which Application Scenarios Are Accelerating Adoption? Long-term maintenance in recurrent or partially remitted patients continues to be dominated by established monoaminergic antidepressants. Companies refine prescribing information and patient education to reduce discontinuation and relapse. In acute crises involving suicidal ideation or behavior, standardized in-hospital management pathways incorporating rapid-acting drugs are emerging, driving the reconfiguration of specialty clinics, day-care units, and psychiatric emergency services. For patients with inadequate prior response, adjunctive use of atypical antipsychotics is now more clearly defined in treatment guidelines and labeling, facilitating combination therapy with psychotherapy. Moreover, stratified shared decision-making has become a global consensus across guidelines, improving oversight of side effects, adherence, and functional recovery, and fostering integrated "medication + psychotherapy + follow-up" service models. Regional Trends — How Are North America, Europe, China, and Asia-Pacific Diverging on the Supply and Demand Sides? North America leads with innovation approvals and real-world evidence integration. Intranasal formulations and adjunctive therapies have been standardized earlier in labeling and clinical application, forming a closed-loop model of tertiary care, in-hospital processes, and community follow-up. Europe emphasizes stratification and shared decision-making, with strict regulatory designations of MAHs and manufacturing sites. Multinationals often adopt regional partnerships for commercialization and supply. In China, under the "Healthy China" framework and expanding mental health infrastructure, specialized capacity building, hotlines, and regional centers have enhanced the system's ability to manage moderate-to-severe and acute cases, while promoting integration of pharmaceuticals and service delivery. Other Asia-Pacific countries focus on school- and workplace-based prevention programs, guided by local suicide-prevention white papers, increasing participation from primary care providers. Across all regions, regulators are placing greater emphasis on risk warnings and pre-prescription evaluation, prompting industry players to align accessibility and compliance as dual priorities. Latest Developments In January 2025, the U.S. FDA approved Spravato (esketamine) for independent use in the treatment of depression (previously approved only in combination with oral antidepressants in specific populations), providing greater flexibility for acute symptom management and treatment pathway design; In July 2024, H. Lundbeck and Takeda announced an adjustment to their U.S. collaboration: starting in 2025, Lundbeck will cease U.S. promotion of vortioxetine (Trintellix) and will instead receive fixed royalties based on net sales for 2025–2026, reallocating resources toward Rexulti and other pipeline assets; In 2025, the U.S. FDA updated Rexulti (brexpiprazole) labeling, reaffirming its evidence as an adjunctive treatment for adult Major Depressive Disorder and summarizing safety data. The molecule's ongoing regulatory progress for agitation associated with Alzheimer's disease has also attracted industry attention. 【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart) https://www.qyresearch.com/reports/6009895/major-depressive-disorder Key Industry Keywords (Embedded Throughout) Major depressive disorder Monoaminergic antidepressants Glutamatergic ketamine Adjunctive atypical antipsychotics Rapid-acting crisis intervention Market Landscape & Recent Data (Last 6 Months, Q4 2025–Q1 2026) The global major depressive disorder market is concentrated among major pharmaceutical companies with CNS (central nervous system) franchises. Key players include Pfizer (desvenlafaxine), Eli Lilly (duloxetine), H. Lundbeck (vortioxetine, brexpiprazole co-commercialization with Otsuka), Otsuka Pharmaceutical (brexpiprazole), AstraZeneca, Takeda Pharmaceutical (vortioxetine U.S. commercialization), AbbVie, Euthymics Bioscience, and Tangram Therapeutics. Three recent developments are reshaping treatment paradigms: FDA approval of Spravato (esketamine) for monotherapy (January 2025) : Previously approved only as adjunctive treatment with oral antidepressants. Expanded indication allows independent use in acute depression, increasing flexibility for crisis intervention and treatment pathway design. Lundbeck and Takeda collaboration adjustment (July 2024) : Lundbeck ceased U.S. promotion of vortioxetine (Trintellix), receiving fixed royalties (2025-2026), reallocating resources toward Rexulti (brexpiprazole) and pipeline assets. FDA labeling update for Rexulti (brexpiprazole) (2025) : Reaffirmed evidence as adjunctive treatment for adult Major Depressive Disorder; ongoing regulatory progress for Alzheimer's agitation attracts industry attention. Strategic Outlook & Recommendations Monoaminergic antidepressants (SSRIs, SNRIs) remain first-line for long-term maintenance (recurrent or partially remitted patients). Pfizer (desvenlafaxine), Eli Lilly (duloxetine), Lundbeck/Takeda (vortioxetine). Glutamatergic rapid-acting drugs (esketamine) for acute suicidal ideation/crisis intervention (in-hospital management). January 2025 FDA monotherapy approval expands use. Adjunctive atypical antipsychotics (brexpiprazole, aripiprazole) for patients with inadequate prior response (augmentation therapy). Otsuka/Lundbeck (Rexulti). Regional trends: North America leads innovation approvals (Spravato, Rexulti). Europe emphasizes stratification and shared decision-making. China expanding mental health infrastructure (Healthy China 2030). Asia-Pacific focusing on school/workplace prevention programs. Key players: Pfizer, Eli Lilly, Lundbeck, Otsuka, Takeda, AbbVie. Contact Us: If you have any queries regarding this report or if you would like further information, please contact us: QY Research Inc. Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States EN: https://www.qyresearch.com E-mail: global@qyresearch.com Tel: 001-626-842-1666(US) JP: https://www.qyresearch.co.jp